Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5′untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 237-247

  Bandyopadhyay, S ^a   Huang, X ^a   Cho, H ^b   Greig, N H ^b   Youdim, M B ^c   Rogers, J T ^a,d  

^a Massachusetts General Hospital   (Israel)

^b NIA   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [4 (2 HYDROXYETHYL)PIPERAZIN 1 YLMETHYL]QUINOLIN 8 OL; AMYLOID PRECURSOR PROTEIN; CLIOQUINOL; COPPER; DEFEROXAMINE; FERRITIN; FERRITIN H; FERRITIN L; IRON; IRON CHELATING AGENT; PIPERAZINE 1; UNCLASSIFIED DRUG; VK 28; ZINC; IRON REGULATORY FACTOR; MESSENGER RNA;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; ARTICLE; BIOASSAY; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON RESPONSIVE ELEMENT; NEUROBIOLOGY; NEUROBLASTOMA CELL; NEUROPATHOLOGY; PRIORITY JOURNAL; CHEMICAL STRUCTURE; COMPARATIVE STUDY; DOSE RESPONSE; GENETICS; GLIOBLASTOMA; METABOLISM; METHODOLOGY; NEUROBLASTOMA; PROTEIN SYNTHESIS; TUMOR CELL LINE; UNTRANSLATED REGION;

AMYLOID BETA-PROTEIN PRECURSOR; CELL LINE, TUMOR; CLIOQUINOL; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; IRON CHELATING AGENTS; IRON-REGULATORY PROTEINS; MODELS, MOLECULAR; NEUROBLASTOMA; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSFECTION; UNTRANSLATED REGIONS;

EID: 34248577510     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_25     Document Type: Article

References (71)

1. Atamna H, Frey WH 2nd (2004) A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci USA 101: 11153-11158
2. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, Mintz J (2000) In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57: 47-53
3. Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: 120-131
4. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J (2004) Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 279: 20378-20386
5. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444
6. Benvenisti-Zarom L, Chen J, Regan RF (2005) The oxidative neurotoxicity of clioquinol. Neuropharmacology 49: 687-694
7. Brittenham G, Nathan D, Oliveieri N, Pippard M, Weatherall D (2003) Deferiprone versus desferrioxamine in thalassaemia, and T2 validation and utility. Lancet 361
8. Bush A (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23: 1031-1038
9. Bush AI (2003) The Metallobiology of Alzheimer's disease. Trends in Neurosciences 26: 207-214
10. Caughey WS, Raymond LD, Horiuchi M, Caughey B (1998) Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 95: 12117-12122
11. Celsi F, Ferri A, D'Amrosi N, Rotliiio G, Costa A, Volonte C, Carri M (2004) Overexpression of superoxide dismutase 1 protects against beta = amyloid peptide toxicity: effect of estrogen and copper chelators. Neurochem Int 44: 25-33
12. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676
13. Chiodo AA, Alberti PW, Sher GD, Francombe WH, Tyler B (1997) Desferrioxamine ototoxicity in an adult transfusion-dependent population. J Otolaryngol 26: 116-122
14. Cox LA, Kennedy MC, Adrian GS (1995) The 5′-untranslated region of human transferrin mRNA, which contains a putative iron-regulatory element, is bound by purified iron-regulatory protein in a sequence-specific manner. Biochem Biophys Res Commun 212: 925-932
15. Crapper McLachlan D, Dalton AJ, Krack TPA, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1308
16. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276: 20466-20473
17. Fillebeen C, Caltagirone A, Martelli A, Moulis JM, Pantopoulos K (2005) IRP1 Ser-711 is a phosphorylation site, critical for regulation of RNA-binding and aconitase activities. Biochem J 388: 143-150
18. Gal S, Zheng H, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95: 79-88
19. Gunshin H, Allerson CR, Polycarpou-Schwarz M, Rolfs A, Rogers JT, Kishi F, Hentze MW, Rouault TA, Andrews NC, Hediger MA (2001) Iron-dependent regulation of the divalent metal ion transporter. FEBS Letters 509: 309-316
20. Gunshin H, Fujiwara Y, Custodio AO, Direnzo C, Robine S, Andrews NC (2005) Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 115: 1258-1266
21. Gutteridge JM (1994) Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann N Y Acad Sci 738: 201-213
22. Halliwell B, Gutteridge JM (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219: 1-14
23. Howlett D, Cutler P, Heales S, Camilleri P (1997) Hemin and related porphyrins inhibit beta-amyloid aggregation. FEBS Lett 417: 249-251
24. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, et al. (1999a) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616
25. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, et al. (1999b) Cu(II) potentiation of Alzheimer A beta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274: 37111-37116
26. Jeffries W, Dickstein D, Ujiie M (2001) Assessing p97 as an Alzheimer's disease serum biomarker. J Alzheimers Dis 3: 339-344
27. Jellinger K, Paulus W, Grandke-Iqbal I, Riederer P, Youdim MB (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2: 327-340
28. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909
29. Killilea DW, Wong SL, Cahaya HS, Atamna H, Ames BN (2004) Iron accumulation during cellular senescence. Ann N Y Acad Sci 1019: 365-367
30. Klausner R, Rouault TA, Harford JB (1993) Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72: 19-28
31. Kontoghiorghes GJ (2005) Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 366: 804
32. Lahiri D, Chen D, Vivien D, Ge Y-W, Greig N, Rogers J (2003) The role of cytokines in the gene expression of amyloid β-protein precursor: identification of a 5′UTR binding nuclear factor and its implications for Alzheimer's disease. JAD 5: 81-90
33. Lahiri DK, Nall C (1995) Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res Mol Brain Res 32: 233-240
34. Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104: 469-481
35. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, Drake SK, Miller G, Abu-Asab M, Tsokos M, et al. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 27: 209-214
36. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52
37. Mainous AG 3rd, Eschenbach SL, Wells BJ, Everett CJ, Gill JM (2005) Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: results from an 18-year population-based cohort. Fam Med 37: 36-42
38. Maloney B, Ge YW, Greig N, Lahiri DK (2004) Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. Faseb J 18: 1288-1290
39. Mbella EG, Bertrand S, Huez G, Octave JN (2000) A GG nucleotide sequence of the 3′ untranslated region of amyloid precursor protein mRNA plays a key role in the regulation of translation and the binding of proteins. Mol Cell Biol 20: 4572-4579
40. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, et al. (2000) A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5: 299-309
41. Nguyen T, Hamby A, Massa SM (2005) Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 11840-11845
42. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT (2003) Drug discovery targeted to the Alzheimer's APP mRNA 5′-untranslated region: the action of paroxetine and dimercaptopropanol. J Mol Neurosci 20: 267-275
43. Phinney A, Drisaldi B, Schmidt S, Lugowski S, Coronado V, Liang Y, Horne P, Yang J, Sekoulidis J, Coomaraswarmy J, et al. (2003) In vivo reduction of amyloid-β by a mutant copper transporter. PNAS 100: 14193-14198
44. Pinero DJ, Hu J, Connor JR (2000) Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains [in process citation]. Cell Mol Biol (Noisy-Le-Grand) 46: 761-776
45. Priola SA, Raines A, Caughey WS (2000) Porphyrin and phthalocyanine antiscrapie compounds [see comments]. Science 287: 1503-1506
46. Rajagopalan LE, Malter JS (2000) Growth factor-mediated stabilization of amyloid precursor protein mRNA is mediated by a conserved 29-nucleotide sequence in the 3′- untranslated region. J Neurochem 74: 52-59
47. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60: 1685-1691
48. Rogers J (2005) APP and Ferritin Translation, Metals and Alzheimer's disease, in Metals and Medicine, Sessler J, ed. J Am Chem Soc pp 215-251
49. Rogers JT, Lahiri DK (2004) Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5: 535-551
50. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN (1999) Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 274: 6421-6431
51. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, et al. (2002a) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277: 45518-45528
52. Rogers JT, Randall J, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, Gullans SR (2002b) Alzheimer's disease drug discovery targeted to the APP mRNA 5′untranslated region. J Mol Neurosci 19: 77-82
53. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C (2001) The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 22: 563-568
54. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46: 254-263
55. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88: 10540-10543
56. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G (1994) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145: 42-47
57. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657
58. Sparks D, Schreurs B (2003) Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. PNAS 100: 11065-11069
59. Thome J, Gsell W, Rosier M, Kornhuber J, Frolich L, Hashimoto E, Zielke B, Wiesbeck GA, Riederer P (1997) Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Life Sci 60: 13-19
60. Thompson K, Menzies S, Muckenthaler M, Torti F, Wood T, Torti S, Nentze M, Beard M, Connor J (2003) Mouse brains deficient in H-ferritin have normal iron concentration but protein profile of iron deficiency and increased oxidative stress. J Neurosci Res 71: 46-63
61. Thomson AM, Cahill CM, Cho HH, Kassachau KD, Epis MR, Bridges KR, Leedman PJ, Rogers JT (2005) The acute box cis-element in human heavy ferritin mRNA 5′-untranslated region is a unique translation enhancer that binds poly(C)-binding proteins. J Biol Chem 280: 30032-30045
62. Ujiie M, Dickstein D, Jeffires W (2002) p97 as a biomarker for Alzheimer's disease. Front Biosci 7: 42-47
63. Venti A, Giordano T, Eder P, Lahiri DK, Greig NH, Rogers JT (2004) The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region. Ann N Y Acad Sci 1035: 34-48
64. Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, et al. (1996) Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14: 3112-3120
65. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Anderson GJ (1999) Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 21: 195-199
66. Wu X, Hasinoff BB (2005) The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 16: 93-99
67. Wu X, Patel D, Hasinoff BB (2004) The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin. J Inorg Biochem 98: 1818-1823
68. Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012: 306-325
69. Zaidi SH, Malter JS (1994) Amyloid precursor protein mRNA stability is controlled by a 29-base element in the 3′-untranslated region. J Biol Chem 269: 24007-24013
70. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873
71. Zhang X, Xie W, Qu S, Pan T, Wang X, Le W (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun 333: 544-549